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Key Points
• TSCM lymphocytes are
preferentially generated from
naive precursors in vivo early
after haploidentical HSCT.
• TSCM represent relevant novel
players in the diversification of
immunological memory after
haploidentical HSCT.
Memory stem T cells (TSCM) have been proposed as key determinants of immunologic
memory. However, their exact contribution to a mounting immune response, as well as
the mechanisms and timing of their in vivo generation, are poorly understood. We lon-
gitudinally tracked TSCM dynamics in patients undergoing haploidentical hematopoi-
etic stem cell transplantation (HSCT), thereby providing novel hints on the contribution
of this subset to posttransplant immune reconstitution in humans. We found that
donor-derived TSCM are highly enriched early after HSCT. We showed at the antigen-
specific and clonal level that TSCM lymphocytes can differentiate directly from naive
precursors infused within the graft and that the extent of TSCM generation might cor-
relate with interleukin 7 serum levels. In vivo fate mapping through T-cell receptor
sequencing allowed defining the in vivo differentiation landscapes of human naive
T cells, supporting the notion that progenies of single naive cells embrace disparate
fates in vivo and highlighting TSCM as relevant novel players in the diversification of immunologicalmemory after allogeneic HSCT.
(Blood. 2015;125(18):2865-2874)
Introduction
Upon antigen recognition, naive T cells (TN) undergo extensive
functional and phenotypic changes that drive their differentiation into
effectors, which are committed to rapidly clearing the pathogen, and
memory cells, which are able to survive long term, to ensure recall
responses in case of pathogen recurrence.1 The memory compartment
is multifaceted and encompasses multiple T-cell subsets with
divergent properties.2 In addition to central memory cells (TCM)
and effector memory cells (TEM),
3 the spectrum of immunological
memory has been recently extended with the identiﬁcation of
memory stem T cells (TSCM).
4,5 Human TSCM lymphocytes express
CD45RA, CCR7, and CD62L TN, but, different from TN and similar
to othermemory subsets, they are characterized byCD95 expression.
Gene expression proﬁling, corroborated by in vitro and in vivo
experimental results, posits TSCM upstream from TCM and TEM in
T-cell ontogeny.4,5 However, whether TSCM represent a stable subset
reproducibly generated on TN priming, and what the relationships
of TSCM with the other memory subsets are, are still controversial
issues. Furthermore, how human TSCM are formed in vivo, what the
instructive signals guiding their formation and/or expansion are, and
when they emerge during the immune response have not yet been
elucidated.
The contribution of different memory T-cell subsets (although not
TSCM) to the generation of effective primary and secondary immune
responses has been elegantly studied at the single-cell level in murine
models.6-10 In humans, however, this pursuit has been limitedby ethical
and technical constraints. Hematopoietic stem cell transplantation
(HSCT) provides a unique setting to longitudinally study the dynamics
of discrete T-cell populations upon transfer directly in humans. During
allogeneic T-replete HSCT, the recipient receives a myeloablative
and lymphodepleting conditioning that abates the host hematopoietic
compartment, followed by the infusion of a graft containing not only
hematopoietic stem cells but also mature T cells from an allogeneic
donor.11 The conditioning regimen induces systemic inﬂammation,
thereby creating a milieu in which infused donor-derived lymphocytes
are exposed to a high (allo)antigenic load. Therefore, close longitudinal
sampling of peripheral blood (PB) and bone marrow (BM) of patients
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after HSCT may allow tracking primary and/or secondary T-cell re-
sponses. We have previously shown that interleukin 7 (IL-7) and IL-15
are necessary to instruct the generation of human TSCM lymphocytes
from naive precursors in vitro and that TSCM, which represent not more
than 2% to 3% of circulating T cells in healthy subjects, are enriched
early after HSCT, when these homeostatic cytokines are particularly
abundant.5 Building on these observations, we investigated when and
how TSCM emerge on transplant in vivo in the clinically relevant setting
of haploidentical HSCT with posttransplant cyclophosphamide
(pt-Cy).12,13 Understanding the complex dynamics of TSCM on allo-
geneic HSCT may ultimately inform on the role of this novel T-cell
subset in posttransplant immune reconstitution (IR) and possibly
provide novel hints on their physiological role.
Methods
Patients, procedures, and biological samples
Twenty consecutive adult patients with high-risk hematologic malignancies
treated with myeloablative haploidentical HSCT in our Hematology Unit at San
Raffaele Scientiﬁc Institute were studied. Patients received treosulfan-based
myeloablative conditioning followedbyanunmanipulatedperipheral bloodgraft
from an HLA-haploidentical related donor. Postgrafting graft-vs-host-disease
(GVHD) prophylaxis consisted of pt-Cy, 50 mg/kg per day, on days 3 and 4,
followed by mycophenolate mofetil (15 mg/kg 3 times a day) for 30 days and
sirolimus (target level, 8-15 ng/mL) for 3 months (supplemental Figure 1A,
available on the BloodWeb site). PB and BM samples of donors, patients, and
healthy subjects were collected after written informed consent was approved by
the San Raffaele Institutional Ethical Committee.
Multiparametric flow cytometry
Mononuclear cells (peripheral blood mononuclear cells; PBMCs) were isolated
from PB and BM by Ficoll-Hypaque gradient separation (Lymphoprep;
Fresenius) and were immediately used for subsequent analyses. All
phenotypic and functional analyses were performed on freshly isolated
samples. Eleven-color immunophenotypic analysis was performed using
a LSRFortessa ﬂow cytometer (BD Biosciences). Each acquisition was
calibrated using Rainbow Calibration Particles (Spherotech) to correct for
day-to-day variation. For intracellular staining, cells were stained with ap-
propriate surface antibodies, washed, and then ﬁxed and permeabilized
with FOXP3 Fix/Perm Buffer Set (Biolegend) following the manufacturer’s
instructions. Data were processed using FlowJo version 9.7.5 (TreeStar).
T-cell subsets were deﬁned according to the expression of CD45RA, CD62L,







1CD62L2. The supplementalMaterial provides detailed infor-
mation on absolute quantiﬁcations, antibodies, ﬂuorochromes, ﬂuorescence-
activated cell sorting, and gating strategy.
Aldefluor assay to determine aldehyde dehydrogenase activity
Aldeﬂuor kit (Stem Cell Technologies) was used, following the manufacturer’s
instructions, to identify cell populations with high aldehyde dehydrogenase
(ALDH) enzymatic activity. Brieﬂy, PBMCs from leukapheresis or from PB
were incubatedwithAldeﬂuor substrate for 30minutes at 37°C,with andwithout
diethylaminobenzaldehyde, and then stained for surface markers. Aldeﬂuor was
detected in the green ﬂuorescence channel, and samples treated with diethyla-
minobenzaldehydewere used as controls to set the gates deﬁning theALDH1
region.
Quantification of serum cytokines
IL-7 and IL-15 serum concentrations were quantiﬁed by Bio-Plex Pro Human
Cytokine 4-plex array (Bio-Rad). Samples were analyzed in duplicate. For each
studied cytokine, a high-sensitivity standard curve was prepared by serial
dilutions of recombinant proteins. Data were analyzed using Bio-Plex
Manager version 6.1 (Bio-Rad).
T-cell receptor B CDR3 region sequencing and analysis
T-cell receptor b (TCRb) chain hypervariable complementarity-determining
region 3 (TCRBCDR3)was ampliﬁed and sequenced fromDNAextracted from
T-cell subsets (TN, TSCM, TCM, and TEM/EFF) ﬂuorescence-activated cell sorter
(FACS)-puriﬁed (purity. 95%) from leukapheresis and from PB harvested 30
days post-HSCT from 3 consecutive patients using the ImmunoSEQ platform at
Adaptive Biotechnologies.14 TCRB CDR3 region was deﬁned as established
by the International ImMunoGeneTics collaboration.15 Sequences that did not
match CDR3 sequences were removed from the analysis. Rearranged CDR3
sequences were classiﬁed as nonproductive if they included insertions or dele-
tions resulting in frameshifts or premature stop codons, and were excluded from
subsequent analyses, according to the ImmunoSEQ validated algorithm. The
average numbers of total productive nucleotide sequences retrieved were
the following: leukapheresis product (LP) samples: TN: 1 197 527, TSCM:
1 140 816, TCM: 2 259 613, and TEM/EFF: 1 416 086; and day 30 samples:
TN: 1 421 741, TSCM: 1 157 884, TCM: 1 288 319, and TEM/EFF: 1 788 812.
Unique CDR3 sequences were identiﬁed and compared using R version 3.0.0.
For T-cell subsets harvested 30 days post-HSCT, only CDR3TCRB sequences
whose reads were higher than 10 were considered for all LP samples and for
the qualitative analyses of day 30 samples (to avoid inclusion of reading errors).
No ﬁlters were applied to day 30 samples for quantitative analyses to ensure
the inclusion of all substantial count reductions, indicative of clone contraction
after infusion. TCRB sequence counts and T-cell subsets were clustered using
Spearman correlation and average linkage; heat maps were drawn using gplots
R package. Circos plots were performed as previously described.16
Statistical analysis
Statistical analyses were performedwith Prism 5 (GraphPad Software). Data are
shown as mean 6 SEM unless otherwise speciﬁed. Data were analyzed with
paired t test when comparing the same subset between different points or with
unpaired t test or standard analysis of variancewhen comparing across 2 ormore
different subsets. For all comparisons, 2-sided P values were used, and P, .05
was considered statistically signiﬁcant. For linear regression analyses, the best-ﬁt
values of the slopes were reported along with goodness-of-ﬁt value (r2), P value
of the slope (F test), and 95% conﬁdence band. Signiﬁcance of the slopes was
independently veriﬁed using R.
Results
Donor-derived TSCM are selectively enriched early after
haploidentical HSCT
To understand the dynamics and fate of human naive and memory
T lymphocytes on HSCT, donor-derived T-cell subsets were longi-
tudinally tracked within the ﬁrst month after infusion into 20
consecutive high-risk hematological patients undergoing haploident-
ical myeloablative T-replete HSCT with pt-Cy. Patient and donor
characteristics are summarized in supplemental Table 1. This HSCT
platform (supplemental Figure 1A) allows tracking of CD31 T cells
even in the ﬁrst 2 weeks post-HSCT, a possibility precluded in
transplants exploiting antithymocyte globulins as an in vivo T-cell-
depleting agent (supplemental Figure 1B). First, to rule out the
possible contribution of residual host-derived lymphocytes to circu-
lating cells, we analyzed peripheral T-cell chimerism in 4 patient-
donor couples mismatched for HLA-A*0201. In both CD41 and
CD81 compartments, host-derived T cells accounted for less than
30% of cells at day 1 after infusion and then decreased to less than
10% at day 5, disappearing by day 15 post-HSCT (supplemental
Figure 2). Therefore, donor-derived T cells dominated even at the
earliest points post-HSCT. On infusion and administration of pt-Cy,
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circulating TN gradually contracted, and by day 8 post-HSCT, the vast
majority of circulating T lymphocytes were characterized by a memory
phenotype (Figure 1A-B), indicating either a preferential sensitivity of
TN to Cy or a massive differentiation of TN into memory/effector cells
in the ﬁrst week after transplant. Strikingly, at day 8 post-HSCT, CD81
TSCM became the most represented circulating subset, in terms of both
frequency and absolute counts (Figure 1C-D). Their frequency at day 8
was signiﬁcantly higher than that within the infused graft (Figure 1D).
CD41 T-cell subpopulations displayed superimposable dynamics
(supplemental Figure 3). In line with TSCM phenotypic characteriza-
tion previously reported,4,5 CD81 and CD41 TSCM at day 8 post
HSCT homogeneously expressed CCR7, CXCR4, CD27, and CD28
(supplemental Figure 4). Notably, serum concentration of IL-7 at
day 1 appeared to correlate with the number of circulating CD81 and
CD41TSCM lymphocytesmeasured at day 8 (Figure 1E; supplemental
Figure 3), but not with TCM or TEM (supplemental Figure 5). At later
points, TCM, TEM, and effectors prevailed, whereas CD8
1 and CD41
TN reappeared at day30post-HSCT(Figure 1; supplemental Figure 3).
These results prompted us to unveil the origin of those TSCM lym-
phocytes highly represented at day 8 post-HSCT.
pt-Cy administration eliminates proliferating T cells but does
not prevent TSCM accumulation
To discern whether the high frequency of TSCM observed at day 8 was
a result of expansion of TSCM infused within the graft or their direct in
vivo generation, we analyzed T-cell subset proliferation, assessed by
Ki-67 staining.17 We hypothesized that TSCM expansion should have
been preceded by proliferation of either TSCM or TN lymphocytes,
assuming dedifferentiation of TCM or TEM to be unlikely.
4 The
accumulation of TSCM in this clinical context should also require such
proliferating TSCM or TN lymphocytes to survive Cy, either for intrinsic
resistance or as a result of temporal uncoupling of proliferation and Cy
administration.
At day 3 on in vivo infusion, in the absence of immunosuppres-
sive drugs, all memory CD81 T-cell subsets robustly proliferated,
with TSCM displaying signiﬁcantly higher frequencies of Ki-67
1 cells
compared with all other subsets (Figure 2A-C). In contrast, only a
minority of TN was Ki-67
1, in line with the longer timeframe required
for priming (Figure 2A-C).CD41T-cell subsets displayed superimpos-
able proliferation kinetics, albeit globally to a lower extent than CD81
(supplemental Figure 6). Cyclophosphamide is a cytotoxic compound
active on proliferating cells, used to purge alloreactive T cells in vivo
and prevent GVHD. T-cell proliferation was abrogated after pt-Cy in
all subsets (Figure 2D), suggesting effective killing of cycling lym-
phocytes. However, T-cell counts did not drop between day 5 and
day 8 post-HSCT (Figure 2B, gray line, right y axis), and TSCM in-
creased in percentages and counts (Figure 1). These results could be
explained either by a selective resistance of cycling TSCM to Cy or by
de novo generation of TSCM. We thus explored whether TSCM were
resistant to pt-Cy. We failed to record ALDH activity in 3 patients
selected according to sample availability, the major mechanism of Cy
inactivation,18,19 in total CD31 T cells neither within the graft nor
after in vivo infusion, in contrast with what observed for coexisting
Figure 1. Donor-derived TSCM lymphocytes are
selectively enriched early after haploidentical HSCT.
(A) Flow cytometric plots of CD81 T-cell phenotype
from a representative patient (UPN#15) within the LP
and at different points after HSCT, as labeled. Top
row plots depict the expression of CD45RA and CD62L,
which allows the identification of TCM (CD45RA
2CD62L1),
TEM (CD45RA
2CD62L2), and TEMRA (CD45RA
1CD62L2).
Quadrant frequencies are indicated. To discriminate
between TN and TSCM, which are both CD45RA
1
CD62L1, double-positive cells are gated and CD95
expression is shown in the bottom row plots. TSCM
are identified as CD951, and TN as CD95
2. The per-
centages of TSCM gated on CD45RA
1 CD62L1 CD81
T lymphocytes are shown. (B) Summary of CD81
T-cell subset distributions, expressed as percentages
on total CD81 T cells, at the indicated points post-
HSCT. (C) Comparison of CD81 T-cell subset fre-
quencies at day 8 post HSCT. Each dot represents
a single patient. (D) Comparison of the absolute
numbers of circulating CD81 T cell subsets at day 8
post-HSCT. (E) Comparison of TSCM frequencies
among LP and day 8 post-HSCT. Data are shown as
mean values 6 SEM of the 20 patients included in the
study. (F) Linear regression analysis between CD81
TSCM counts at day 8 post-HSCT and the serum level
of IL-7 measured at day 1 post-HSCT (n5 13). Gray line
denotes the best-fit line of the linear regression analysis,
whereas black dashed lines indicate the 95% confidence
interval. The r2 and P value of the slope are reported in
the upper-right part of the panel.
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CD341 HSCs, analyzed as internal controls (Figure 2E-F). Accord-
ingly,wedetectedhighpercentages of apoptotic cellswithin allmemory
subsets at day 5 post-HSCT (1 day after pt-Cy). Noticeably, at day 8,
signiﬁcantly lower percentages of CD81 TSCM were Annexin V
1
compared with TCM, TEM, and TEMRA, whereas by day 15, post-
HSCT, all memory subsets displayed very low levels of apoptosis
(Figure 2H). Altogether, these results suggest that nonapoptotic day 8
TSCM might stem from de novo differentiation from TN lymphocytes.
CD41 TSCM preferentially retain CD31 expression by day 8
post-HSCT
To gain further insight on the possible in vivo differentiation of infused
TN lymphocytes into TSCM, we ﬁrst exploited the peculiar kinetics
of CD31 expression. CD41 TN recently exited from thymus can be
identiﬁed according to the expression of CD31, which is gradually lost
on proliferation.20 Importantly, in healthy adults, only a minority of
circulating CD41 TSCM, TCM, and TEM lymphocytes express CD31
(Figure 3A). We reasoned that upon or after in vivo priming of donor-
derived CD41TN, CD31 expression could be detected in their progeny
if the analyzed point (day 8 post-HSCT) was sufﬁciently close to the
priming to avoid excessive dilution, thereby representing a tool to track
TN differentiation by ﬂow cytometry. To verify this hypothesis, puriﬁed
CD311 CD41 TN from 3 healthy subjects were CFSE-labeled and
polyclonally stimulated in the presence of IL-7 and IL-15. Eight days
after stimulation, CD31 expression was retrieved on the postmitotic
progeny of stimulated TN, which had acquired memory features (sup-
plemental Figure 7), indicating that CD31 downregulation kinetics on
RTEs can be exploited to track their fate in vivo. Therefore,we analyzed
the kinetics of CD31 expression on CD41 T-cell subsets in our cohort
of patients (Figure 3C-E). Similar to healthy controls, within the in-
fused graft, a signiﬁcantly higher fraction of CD41 TN expressed
CD31 compared with all memory subsets, including TSCM, and the
percentages (and expression levels) of CD311TN, TSCM, TCM, andTEM
did not vary until day 3 post-HSCT (Figure 3C-E). Notably, at day 8,
when TN disappeared from circulation (Figure 3D), CD31
1 clustered
predominantly within the TSCM compartment, suggesting recent dif-
ferentiation from TN precursors. By day 30 post-HSCT, expression
of CD31 on CD41 TSCM was signiﬁcantly reduced compared with
day 8, whereas CD311 TN were again detectable, in line with de novo
Figure 2. pt-Cy administration abrogates T-cell
proliferation but does not prevent accumulation of
TSCM. (A) Flow cytometry plots depict Ki-67 expression
on CD81 T cell subsets from a representative patient
(UPN#20) at different points after HSCT, as labeled.
Gray arrow denotes pt-Cy administration. (B) Summary
of the percentages of proliferating CD81 T cell subsets
at the indicated points post-HSCT. Gray line designates
absolute CD81 T cell counts. Gray shade indicates pt-Cy
administration. (C) Comparison of the percentage of
Ki-671 cells among the different CD81 T-cell subsets at
day 3 post-HSCT (before pt-Cy administration and in the
absence of any immunosuppressive agent). (D) Com-
parison of the percentages of proliferating cells before
pt-Cy administration (day 3) and at the point when
highest TSCM frequencies were detected (day 8). (E)
Flow cytometric plots of ALDH enzymatic activity
from a representative patient (UPN#17) of the 4
patients tested for ALDH activity. Top row plots show
ALDH1 cells at the labeled points, whereas bottom row
plots show CD34 and CD3 expression on ALDH1 gated
cells. (F) Scatter plot depicts the mean percentage of
circulating ALDH1 cells at the indicated points. (G)
Scatter plot shows the belonging lineage of ALDH1 cells
at the labeled points: CD341 cells are indicated with
open circles, CD31 cells with black triangles (n 5 4). (H)
Percentages of Annexin V1 early apoptotic cells within
CD81 T cell subsets at days 5, 8, and 15 post-HSCT.
Dashed black line indicates mean percentage of
Annexin V1 cells measured in leukapheresis (n 5 3).
n.e., not evaluable.
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generation, conﬁrmed by sjTREC analysis performed on day 30 cells
(supplemental Figure 8). Overall, these data suggest that CD311CD41
TSCM observed at day 8 post-HSCT preferentially derive from CD31
1
CD41 TN infused within the graft.
Conversion of CD81 TN into TSCM can be traced at the
antigen-specific level
To trace the differentiation of antigen-speciﬁc21 CD81 TN into TSCM,
we exploited HLA-A*0201 and HLA-A*0101 dextramer complexes
loaded with known immunogenic peptides fromWT122 or PRAME23
in PB or BM of leukemic patients. Tumor-speciﬁc T cells are usually
rare inhealthy subjects and,whendetectable, invariantlydisplay anaive
phenotype (4). Indeed, in UPN#4, rare HLA-A*0101 restricted WT1-
speciﬁc T cells retrieved in the donor LP displayed a TN phenotype. By
day 30 after HSCT, WT1-speciﬁc T cells displayed memory features
andwere traceable both inPBandat diseasesite (BM),withTSCMbeing
detectable in the latter (Figure 4A). The same result was obtained in
UPN#13, mismatched with the donor for HLA-A*0201. We traced
tumor-speciﬁc T cells in 3 additional patients receiving a transplant
matched for the restriction element analyzed. Of notice, tumor-speciﬁc
Tcells detected inLPdisplayed aTNphenotype,whereas after infusion,
antitumor T cells acquired a memory phenotype in all patients and
comprised TSCM lymphocytes, although their relative contribution var-
ied across different anatomical sites and different patients (Figure 4B).
In our series, only 1 cytomegalovirus-seropositive HLA-B*07021 pa-
tient was transplanted from a cytomegalovirus-seronegative donor,
allowing us to potentially trace a viral-speciﬁc primary immune re-
sponse. Accordingly, pp65-speciﬁc T cells in LP displayed a naive
phenotype.We observed the appearance of pp65-speciﬁcCD81TSCM,
in concomitance with viral reactivation (supplemental Figure 9). Over-
all, these observations support direct conversion of human CD81 TN
into TSCM in vivo.
In vivo fate mapping by TCR clonotyping uncovers the
differentiation landscapes of TN after transplant
To assess the relevance of in vivo differentiation of TSCM fromTN after
transplant, we exploited the TCR sequences harbored by individual
T lymphocytes as surrogate clonal markers to track T-cell fate on
infusion. CD31 TN, TSCM, TCM, and TEM/EFF were FACS-puriﬁed
from LP and PBMCs harvested 30 days after HSCT in 3 consecutive
patients and were subjected to TCRB CDR3 deep sequencing. First,
we observed that the TCRB repertoire detected at day 30 in TN did
not overlap with that of the other T-cell subsets retrieved at day 30
(supplemental Figure 10), suggesting the majority of day 30 TN arise
fromde novo generation. For longitudinal evaluation, CDR3TCRB in-
frame nucleotide sequences unique to each T-cell subset within LP
samples were identiﬁed. These speciﬁc rearrangements were used to
estimate qualitatively and quantitatively the fate after infusion of T cells
Figure 3. CD41 TSCM preferentially retain CD31
expression by day 8 post-HSCT. (A) Box plots depict
the differential expression of CD31 on CD41 T-cell sub-
sets (TN, TSCM, TCM, and TEM) from healthy subjects
(n 5 25). (B) Flow cytometry plots of CD31 expression
on CD41 TN, TSCM, TCM, and TEM from a representative
patient (UPN#4) at different points after HSCT, as
labeled. (C) Kinetics of representation of TN and TSCM,
expressed as percentage on the total circulating CD41
cells at the indicated points post-HSCT. TCM and TEM
kinetics are also depicted (gray dashed lines). (D) Box
plots show CD31 expression on CD41 TN, TSCM, TCM,
and TEM at the labeled points. Data are shown as average
values from the 20 patients included in the study. n.e.:
not evaluable.
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bearing a speciﬁc differentiation phenotype within LP. As expected,
sequences harbored by TN lymphocytes within LP were retrieved
in all memory subsets at day 30, showing that after HSCT, TN are
able to generate the complete spectrum of immunological memory,
includingTSCM, that represented, on average, 32%ofmemoryT cells
(Figure 5A), implying that during TN differentiation after transplant,
a high number of TSCM is generated. Similarly, TCRB sequences
originally harbored by LP-TSCMwere found in all memory subsets at
day 30 post-HSCT. Conversely, sequences present in LP-TCM were
retrieved preferentially in TCM and TEM/EFF repertoires at day 30
post-HSCT, whereas fewer than 10% were found in the TSCM rep-
ertoire. Sequences harbored by LP-TEM/EFF were found mainly
within day 30 TEM/EFF, although conversion into TCM was also
observed (27%). Again, less than 10% of TCRB sequences iden-
tiﬁed in LP-TEM/EFF were retrieved in the TSCM compartment at
day 30 (Figure 5A). These data are consistent with a preferential
progressive framework of differentiation, following the pathway
TN→TSCM→TCM→TEM/EFF, but still allowing for a certain degree
Figure 4. Conversion of CD81 TN into TSCM can be
demonstrated at the antigen-specific level. (A)
Identification of WT1-specific CD81 T cells restricted
to the host nonshared HLA-A*0101 by dextramer stain-
ing of, from top to bottom, donor LP, day 30 peripheral
blood, and day 30 BM harvested from UPN#4. For each
point analyzed, left plot depicts the percentage of
dextramer-positive CD81 T cells (WT1-dex). Dextramers
carrying the same restriction element but loaded with
an irrelevant peptide were used to set the gate and dis-
tinguish rare antigen-specific cells from background.
Central plot shows CD45RA and CD62L expression
on dextramer-positive cells (quadrants are set on the
polyclonal CD81 population). Right plot depicts CD95
expression on CD45RA1CD62L1 cells when detected
(CD95 gate is set on the polyclonal CD81 population).
(B) Histograms summarizing the quantification and pheno-
typic characterization of CD81 T cells specific for
either WT1 (UPN#4, UPN#8, UPN#11, and UPN#13)
or PRAME (UPN#2) in 5 patients affected by acute
leukemia and with HLA typing suitable for dextramer
analysis. For all cytometric dextramer acquisitions, no
fewer than 1 3 106 cells were stained and no fewer than
105 events on the CD31 gate were recorded. n.a., sample
not available; n.e., population not evaluable.
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of plasticity within each memory subset. Quantitative analysis re-
vealed that only clonotypes originally harbored by LP-TN were sig-
niﬁcantly increased in counts at day 30 post-HSCT, regardless of the
subsets in which they were identiﬁed after transplant (Figure 5B
depicting 1 representative patient; supplemental Figures 11 and 12
for the remaining 2 patients analyzed). In accordance with ﬂow-
cytometric data (Figure 2), sequences unique to LP-TSCM, LP-TCM,
or LP-TEM/EFFwere similar or reduced in counts at day 30 post-HSCT
compared with LP, indicating that pt-Cy efﬁciently dampened their
expansion and that possibly only memory lymphocytes that
remained unchallenged on in vivo infusion could survive pt-Cy
(Figure 5B; supplemental Figures 11 and 12). T-cell responses
are characterized by the clonal burst of the ancestor lymphocyte recog-
nizing its antigen. Given the absence of expansion on infusion,
LP-TSCM, LP-TCM, and LP-TEM/EFF clonotypes were not considered
informative enough to study memory T-cell dynamics in this trans-
plant setting, and we focused on LP-TN. To gain insight into the
differentiation routes adopted by TN on priming, we evaluated the
overlap of the TCRB repertoire from LP-TN with that of memory
subsets retrieved at day 30 post-HSCT. The majority (on average,
80%) of clonotypes of LP-TN lymphocytes retrieved 30 days after
transplant displayed a unique differentiation phenotype, with TSCM
and TCM beingmore represented than TEM/EFF. Only 12% of LP-TN
TCRBsequenceswere found inmultiplememory subsets (Figure 5C-D;
supplemental Figure 13). By focusing on those LP-TN-derived se-
quences that were shared among 2 or more memory subsets at day 30
post-HSCT, we found that approximately 25% of TCRB sequences
were shared among day 30 TSCM, TCM, and TEM/EFF, although all
other possible combinations could be retrieved (Figure 5D-E).
The frequency of memory T-cell clones originating from individual
Figure 5. In vivo fate mapping by TCR clonotyping
uncovers the differentiation landscapes of TN after
transplant. (A) Graphic representation of the distribu-
tion within day 30 memory T-cell subsets of the TCRB
sequences harbored by a given T-cell subset from
LP. Numbers in donut graphs indicate the average
percentages, from the 3 patients analyzed, of TCRB
sequences retrieved in the indicated memory subsets
30 days after HSCT. (B) Quantification of the expan-
sion ability of single-cell progenies of T lymphocytes
with a given phenotype within LP, independent of the
memory T-cell subset in which they were retrieved at
day 30 post-HSCT. Expansion is measured as fold
change of TCRB sequence count at day 30 relative to
LP from a representative patient (UPN#12). (C) Circos
plot16 graphically summarizes the distribution of TCRB
sequences originally harbored by LP-TN in a represen-
tative patient (UPN#12) of the 3 analyzed. LP-TN
sequences are depicted in the bottom part of the circle,
identified by the green band. From each LP-TN-derived
TCRB sequence departs a ribbon connecting it to 1 or
more memory subsets at day 30 post-HSCT. Each day
30 memory subset is denoted by a colored band (red
for TSCM, orange for TCM, and blue for TEM/EFF). Ribbon
thickness is proportional to the TCRB sequence count
of the given clonotype at day 30 post-HSCT. (D) Left
pie chart shows the distribution at day 30 after trans-
plant of the TCRB sequences originally harbored
by LP-TN. Numbers in the pie indicate the average
percentages from the 3 patients analyzed; right chart
zooms on the fraction of clonotypes that were found
shared among 2 or more subsets at day 30 post-HSCT
and depicts the mean distribution of all combinations
retrieved. (E) Spearman correlation heat map represent-
ing the contribution of individual LP-TN-derived clono-
types (row) to the repertoire of TSCM, TCM, and TEM/EFF
subsets at day 30 post-HSCT (columns). The analysis
is performed to LP-TN TCRB sequences that are shared
by at least 2 memory T-cell subsets at day 30 post-
HSCT. (F) Box plots quantify the expansion, measured
as count fold change relative to LP, of LP-TN TCRB
sequences that were retrieved in memory T-cell subsets
at day 30 post-HSCT. (G) Model scheme of a proposed
branched diversification pathway from TN to TSCM, TCM,
and TEM/EFF subsets on in vivo transfer after HSCT.
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LP-TN was highly variable and was proportional to the level of
memory subset diversiﬁcation retrieved at day 30 post-HSCT
(Figure 5F), suggesting that the single-cell progenies differen-
tiating into multiple subsets were those characterized by the high-
est clonal burst. Although the relative contribution of single vs
multiple fates of TN could not be determined, our in vivo fate mapp-
ing suggests that in the HSCT context, progenies of single TNmight
embrace disparate fates, with phenotypic and functional hetero-
geneity achieved at population level. Thus, we propose a revision
of the linear differentiation model to take into account the dis-
cordance in fate of individual TN and the intrinsic plasticity of the
memory compartment, leading to a branched differentiation model
(Figure 5G).
Discussion
Although stem cell engraftment and hematological reconstitution are
carefully monitored during the ﬁrst month after HSCT, the shape of
T-cell dynamics within this timeframe has remained largely unknown
so far. Here, we exploited the pt-Cy platform that, in contrast to other
HSCT protocols that mainly rely on the infusion of antithymocyte
globulins, permits a thorough analysis of circulating cells in this delicate
early posttransplant phase, which allows us to explore the contribution
of TSCM to posttransplant IR. Indeed, we observed that donor-derived
TSCM lymphocytes are highly enriched early after HSCT, and we
showed, at the polyclonal, antigen-speciﬁc, and clonal level, that
TSCM lymphocytes arising soon after HSCT preferentially derive
from differentiation of TN infused within the graft, whereas most
memory lymphocytes are purged by pt-Cy. The observation that Cy
differentially affects naive andmemory T cells in vivo, because of their
different activation kinetics, might provide novel hints on the cellular
determinants of alloreactivity after transplant, which is a matter of
intense debate in the ﬁeld.24,25 Indeed, our results, crossed with the
high clinical efﬁcacy of pt-Cy in preventing GVHD after HLA-
matched26 and haploidentical HSCT,27-29 suggest that alloreactivity in
humans largely segregates with infused memory lymphocytes and is
thereby likely fueled by cross reactivity.30 In contrast, our results imply
that the surviving progenies of TN in this speciﬁcHSCT setting acquire
a leading role in guiding IR. Given the observed high fraction of TN
that differentiates into TSCM after transplant, it will be important to
include CD95 in future studies aiming at deciphering IR kinetics after
allogeneic HSCT, to avoid TN overestimation, and to quantify the
contribution of TSCM.
Notably, we showed that IL-7 serum levels measured 1 day after
graft infusion seem to correlate with circulating TSCM counts at day 8,
thereby suggesting that IL-7might be important for TSCM generation
not only in vitro5 but also in vivo. The cytokinemilieu inwhich T cells
are activated may differently promote effector vs memory differ-
entiation.31,32 We could speculate that the increase in circulating IL-7
levels characteristic of the early phase post-HSCT, and associatedwith
the lymphopenic environment, may have favored TSCM generation in
this speciﬁc context, as also suggested by murine studies.33 Thus, it
remains to be evaluated whether these results could be conﬁrmed in
other relevant human settings, such as longitudinal studies on vacci-
nations or chronic infections, where IL-7 is not elevated and other
possibly confounding variables, such as postgrafting pharmacological
immune suppression with mycophenolate mofetil and sirolimus that
could inﬂuence T-cell metabolism and differentiation, are not present.
Of notice, Roberto et al34 report in this issue of Blood that in a similar
transplant setting, transferred naive T cells rapidly differentiate into
TSCM, which subsequently reconstitute the posttransplant T-cell com-
partment. Importantly, our work and the work by Roberto et al rely on
2 separate models of haploidentical HSCT with major differences in
the conditioning regimen used (myeloablative vs nonmyeloablative),
stem cell source (peripheral blood vs bone marrow), postgrafting
GVHD prophylaxis (mTOR inhibitors vs calcineurin inhibitors), and
disease background (acute leukemia vs lymphoma). Regardless of
these important differences, both studies ultimately reach a similar
model of human T-cell differentiation, with a predominant role played
by TSCM lymphocytes, thus suggesting that generation of TSCM after
transplant is not deeply inﬂuenced by any of these variables. It remains
to be elucidated whether such an IR proﬁle could also be observed in
pediatric patients undergoing haploidentical HSCT with pt-Cy.
Several lines of evidence support the relevance of our ﬁndings in
other clinical contexts. Approximately 30% of virus-speciﬁc memory
cells in yellow fever-vaccinated subjects have been reported to express
CD45RA and CCR7 and to persist for years.35,36 Similarly, another
study identiﬁedCD45RA1CCR71HIV-speciﬁcCD81memoryTcells
functioning as precursors for the other subsets of memory lympho-
cytes.37 Notably, in EBV carriers, 10% of EBV-speciﬁcmemoryCD41
T cells coexpress CD45RA and CCR7.38 Although formal proof that
such cells represented TSCM lymphocytes was missing in these reports,
these ﬁndings strongly support the hypothesis that TSCM lymphocytes
are reproducibly generated after immunization in humans. Differences
in the insulting pathogens and tissue environmentsmight impinge on the
relative abundance of TSCM generated. Here, we show that TSCM have
the potential to emerge early after TN priming, without necessarily pass-
ing through an effector stage.
The mechanisms of T-cell memory formation have been actively
debated and several models proposed to explain the divergent devel-
opmental fates of T-cell progenies. By exploiting the TCR harbored by
single T cells infused within the leukapheresis product as surrogate
clonal markers, we attempted to evaluate the in vivo differentiation
landscapes of single T-cell progenies after transplant in 3 consecutive
patients. Obviously, in the absence of access to secondary lymphoid
organs, peripheral or mucosal tissues, which are constraints typical of
studies involving human subjects, we relied on PB as barometer of the
entire organism, and tissue-resident progenies of infused lymphocytes
could not be included in the present model. With this caveat in mind,
we found that after transfer, discrete T-cell subsets behaved preferenti-
ally within a progressive framework of differentiation: infused TN and
TSCM were able to reconstitute the entire spectrum of T-cell memory.
Interestingly, up to 30% of cells originally TEM could revert to a TCM
phenotype, as reported in nonhuman primates.39 A limited fraction of
TCM and TEM reconverted to TSCM, indicating that the T-cell memory
compartment is endowedwith a certain degree of plasticity in vivo.Our
experimental system was characterized by the use of pt-Cy, which we
showed to selectively kill the majority of memory T cells proliferating
early after transplant. As a result, TCRB sequences originally harbored
by LP-TSCM, LP-TCM, and LP-TEM were found decreased in counts
30 days after transplant. Differently, TN were capable of robustly
proliferating and differentiating into memory cells. Progenies of
individual TN were plastic and had the ability to generate hetero-
geneous effector and memory populations comprising TSCM. Nota-
bly, the experimental evidence that a third of LP-TN clonotypes
traced 30 days after HSCT were found within the TSCM compartment
argues against the hypothesis that TSCM may represent a metastable
state within a continuum of phenotypes but, rather, reinforces the
notion that they represent a stable and relevant memory subset. In
our study, only a small proportion of TN-progenies were traceable in
multiple subsets at day 30, whereas the majority of TN clones
identiﬁed in LP were retrieved in a single memory subclass in vivo.
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Although the relative contribution of single vs multiple cell fates could
not be precisely estimated, our data suggest that the rules of memory
T-cell differentiation in humans are at least in part based on population
averaging of disparate single-cell behaviors and are reminiscent of
the T-cell dynamics recently described in murine models.6,7,10
Altogether, these results highlight TSCM lineage as a previously
unappreciated important player in the diversiﬁcation of TN and will
likely inform strategies aimed at preventing and treating infections,40
autoimmune diseases,41 and cancer.42
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